a Department of Urology , University Hospital Bonn , Bonn , Germany.
b Institute of Pathology , University Hospital Bonn , Bonn , Germany.
Expert Rev Mol Diagn. 2016 Oct;16(10):1059-1065. doi: 10.1080/14737159.2016.1239531. Epub 2016 Sep 27.
Bodily fluids like serum and plasma contain significant amounts of tumor-derived circulating cell-free RNA, which holds the potential to serve as diagnostic biomarker. Consequently, liquid biopsies comprising circulating cell-free RNA might help to facilitate personalized treatment strategies for patients with renal cell carcinoma (RCC). Areas covered: The present review provides a summary of the literature obtained by a PubMed search and covers the current knowledge on circulating non-coding cell-free RNA in patients with RCC. Expert commentary: Altered circulating microRNA and long non-coding RNAs signatures allow for the discrimination of patients with RCC and healthy individuals. On the other hand, little is known about non-coding RNA expression in benign tumors. Cell-free microRNA expression levels may help to identify patients at risk for disease recurrence. However, accurate determination of cell-free RNAs is methodologically challenging and currently no biomarker candidate has reached a sufficient level of clinical validation. Thus, short-term implementation of cell-free circulating microRNA into clinical routine seems unlikely.
体液，如血清和血浆，含有大量肿瘤衍生的循环无细胞 RNA，这些 RNA 有可能作为诊断生物标志物。因此，包含循环无细胞 RNA 的液体活检可能有助于为肾细胞癌 (RCC) 患者制定个性化的治疗策略。
本综述通过 PubMed 检索提供了文献总结，涵盖了 RCC 患者循环非编码无细胞 RNA 的最新知识。
改变的循环 microRNA 和长非编码 RNA 特征允许区分 RCC 患者和健康个体。另一方面，关于良性肿瘤中非编码 RNA 表达知之甚少。无细胞 microRNA 表达水平可帮助识别有疾病复发风险的患者。然而，准确确定无细胞 RNA 具有方法学上的挑战性，目前没有一种生物标志物候选物达到足够的临床验证水平。因此，短期内将循环无细胞 microRNA 纳入临床常规似乎不太可能。
